Top Markets
Coin of the day
Beta Bionics, Inc. Beta Bionics, Inc.

Beta Bionics, Inc.

BBNX
주식 순위 #10096
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated... Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
주가
$19.81
마지막 동기화: 2026-08-28
시가총액
$891.32M
변동 (1일)
1.39%
변동 (1년)
5.16%
국가
US
거래 Beta Bionics, Inc. (BBNX)

카테고리

Beta Bionics, Inc. (BBNX)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Beta Bionics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Beta Bionics, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
3.7944 -
US
5.423 -
US
2.0146 -
IE
3.072 -
US
- -
DE